Cardiovascular involvement in blood cancers: ALL, AML, CLL, and CML

  • Amer Yazdanparast Department of Pediatrics, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
  • Gholamreza Fathpour Al-Zahra Heart Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
  • Shirin Saberianpour Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords: Acute lymphocytic leukemia, Acute myelogenous leukemia, Cancer, Cardiovascular disease

Abstract

Global cancer statistics will continue to grow in the coming years. Leukemia is the fifth leading cause of death in the world and the second one in Iran; therefore, it is very important to study the affected areas, including the cardiovascular system in this disease. In heart cancer, tumors whose primary origin is the heart are called primary tumors, which are very rare. Tumors that originate in other parts of the body and spread to the heart are called secondary tumors. Although heart cancer is still rare, most cancers found in the heart come from other parts of the body and are considered as secondary tumors. The symptoms of metastatic heart cancer vary and depend on the location and extent of the lesion. Cancer can also affect the heart in other ways. One of these ways is the effect of the treatments used, which is reported among acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia due to the use of tyrosine kinase inhibitors as the main drug in reducing mortality among these patients. Pericardial involvement is reported to be the most common cardiovascular complication of drug use among different kinds of leukemias. In this article, we try to collect cardiovascular evidence related to acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia, separately.

Published
2021-09-12
Section
Articles